Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Jade Biosciences (Nasdaq: JBIO) outlined 2026 objectives to advance a pipeline of monoclonal antibodies across autoimmune diseases and will present at the J.P. Morgan Healthcare Conference on January 15, 2026.

Key program milestones include JADE101 Phase 1 interim biomarker data in H1 2026 and a planned Phase 2 start in mid-2026 for IgA nephropathy; JADE201 first-in-human start in Q2 2026 with interim data expected in 2027; and nominated JADE301 entering first-in-human study in H1 2027. The company reported approximately $336 million cash and investments as of December 31, 2025, expected to fund operations into H1 2028.

Positive

• Approximately $336 million cash, cash equivalents, and investments as of Dec 31, 2025
• JADE101 Phase 1 interim biomarker data expected in H1 2026
• JADE201 first-in-human study planned to begin in Q2 2026

Negative

• Cash estimate is preliminary, unaudited and subject to change upon close and audit
• Lead program JADE101 has no patient efficacy data yet; Phase 2 initiation planned for mid-2026

Key Figures

Cash & investments $336 million Estimated as of December 31, 2025; preliminary and unaudited

Runway guidance Into first half of 2028 Funded period based on cash, cash equivalents and investments

JADE101 Phase 1 interim First half of 2026 Healthy volunteer biomarker-rich interim data timing

JADE101 Phase 2 start Mid-2026 Phase 2 IgA nephropathy trial initiation

JADE101 Phase 2 data 2027 Preliminary Phase 2 readout timing in IgA nephropathy

JADE201 first-in-human Q2 2026 Rheumatoid arthritis single ascending dose study start

JADE201 interim data 2027 Initial clinical data from JADE201 first-in-human trial

JADE301 Phase 1 start First half of 2027 First-in-human trial for third antibody program

Market Reality Check

$13.19 Last Close

Volume Volume 236,254 is below the 20-day average of 420,194 (relative volume 0.56). low

Technical Price $14.16 is trading above the 200-day MA at $9.59 and 20.05% below the 52-week high of $17.71.

Peers on Argus

JBIO fell 8.23% while peers were mixed: ALLO -2.17%, AVIR -2.25%, RAPT -6.13%, RNAC -7.27%, and IVVD +1.21%, pointing to a more stock-specific move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Financing / capital raise	Positive	+1.8%	$45M private placement to support R&D and corporate needs.
Nov 13	Earnings & update	Positive	-3.2%	Q3 2025 results highlighting pipeline progress and major financing.
Nov 03	Conference participation	Neutral	-3.4%	Investor conference appearances and webcast availability in Nov 2025.
Oct 17	Clinical data preview	Positive	+6.7%	New JADE101 preclinical and translational data at ASN Kidney Week.
Oct 07	Program initiation	Positive	-1.1%	Announcement of JADE201 anti-BAFF-R candidate and Phase 1 plans.

Pattern Detected

Recent news often highlighted financing strength and pipeline progress; price reactions have been mixed, with some positive clinical updates sold off and financing news sometimes tracking positively.

Recent Company History

Over the last few months, Jade reported multiple financing and pipeline milestones, including a $45 million private placement on Dec 15, 2025 and Q3 2025 results with pro forma cash of $325.6 million and runway into the first half of 2028. Clinical communications emphasized JADE101 and JADE201 progress, including ASN Kidney Week 2025 data and first-in-human plans. Today’s 2026 objectives update extends that trajectory, reaffirming biomarker-rich JADE101 timelines, first-in-human JADE201 in 2026, and preclinical advancement of JADE301 against a reinforced cash position.

Market Pulse Summary

The stock moved -7.3% in the session following this news. A negative reaction despite detailed 2026 objectives fits prior instances where positive updates, such as Q3 2025 progress, were followed by weak price action. The market may have focused on the long runway to key data, with major readouts not anticipated until 2027, even though cash of about $336 million is expected to fund operations into the first half of 2028. Historical patterns suggest news-driven pops have not always been sustained around pipeline communications.

Key Terms

monoclonal antibodies medical

"pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases"

Monoclonal antibodies are lab-made proteins designed to bind a single, specific target on cells or viruses, like identical keys cut to fit one lock. They are used as medicines, tests, or targeted delivery tools and can precisely block or mark disease processes. Investors care because they can become high-value drugs with large sales, long patent protection, and binary risks tied to clinical trial results, regulatory approval, manufacturing scale and pricing.

IgA nephropathy medical

"Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin"

A kidney disease caused when deposits of the antibody called IgA collect in the tiny filters of the kidney, gradually reducing their ability to clear waste — like grit building up in a water filter. It matters to investors because it creates demand for diagnostics, drugs and long‑term care, drives clinical trial activity and regulatory decisions, and can influence the financial outlook of companies in pharma, biotech, medical devices and health insurance.

anti-BAFF receptor antibody medical

"JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance"

An anti-BAFF receptor antibody is a laboratory-made protein that sticks to the BAFF receptor on certain immune cells (B cells) and blocks the signals that help those cells survive and multiply. For investors, this matters because such drugs can treat autoimmune diseases or B‑cell cancers by dialing down or redirecting the immune response, and trial results, approvals, or safety concerns can strongly affect a drug developer’s value.

pharmacokinetic medical

"favorable and differentiated preclinical safety, pharmacokinetic and pharmacodynamic profile"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

pharmacodynamic medical

"favorable and differentiated preclinical safety, pharmacokinetic and pharmacodynamic profile"

Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

placebo-controlled medical

"The randomized, placebo-controlled, single ascending dose trial will evaluate safety"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

single ascending dose medical

"The randomized, placebo-controlled, single ascending dose trial will evaluate safety"

A single ascending dose is a method used in testing new medicines where small amounts are given to participants, gradually increasing each time to find the safest and most effective dose. For investors, it provides important information about a drug’s safety and potential, helping gauge the progress and prospects of a pharmaceutical development.

biomarker-rich medical

"Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected"

A biomarker-rich sample, study or patient group contains a large number of measurable biological indicators (such as genes, proteins or chemical signals) that can help detect disease, predict who will respond to a treatment, or show whether a drug is working. For investors this matters because having lots of reliable markers is like having many fingerprints to match — it can make drug development and clinical trials more efficient, reduce uncertainty, and increase the chances of a clear regulatory or commercial outcome.

AI-generated analysis. Not financial advice.

• JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 
• Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027
• JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027
• Third development candidate, JADE301, nominated; currently in preclinical development; Phase 1 clinical trial expected to commence in the first half of 2027
• Approximately $336 million of cash, cash equivalents, and investments as of December 31^st, 2025 expected to provide runway into the first half of 2028
• Company to present at the 44^th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 a.m. PT
  

SAN FRANCISCO and VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its 2026 strategic priorities, including anticipated milestones ahead of the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco, California.

“2026 is expected to be another year of rapid growth for Jade as we advance our pipeline across multiple clinical trials and transition toward late-stage development for our lead candidate, JADE101” said Tom Frohlich, Chief Executive Officer of Jade Biosciences. “With interim Phase 1 data and Phase 2 initiation anticipated for JADE101 in IgA nephropathy, the planned Phase 1 start of our anti-BAFF-R program, JADE201, and continued investment in discovery-stage antibody innovation, we are executing on a focused strategy to build a next-generation autoimmune company. Our programs are designed to deliver deeper, more durable efficacy with a lower treatment burden for patients. Backed by a strong balance sheet with runway expected to last into the first half of 2028, we enter the year poised to deliver meaningful benefit to patients, have impactful clinical catalysts, and drive long-term growth and value creation.”

Key Program Updates

JADE101: Novel Anti-APRIL Monoclonal Antibody in Development for IgAN

JADE101 is an investigational, fully human monoclonal antibody designed to selectively inhibit A Proliferation-Inducing Ligand (APRIL), a key driver of pathogenic IgA production in patients with IgA nephropathy (IgAN), a progressive autoimmune kidney disease that can lead to kidney failure. Currently in Phase 1 testing in healthy volunteers, JADE101 has demonstrated ultra-high binding affinity in preclinical studies and is engineered for half-life extension, aiming to combine the disease-modifying efficacy of the anti-APRIL mechanism through a long dosing interval with patient-friendly subcutaneous dosing. Its favorable and differentiated preclinical safety, pharmacokinetic and pharmacodynamic profile in non-human primates supports the potential for infrequent dosing and a best-in-class therapeutic profile.

Jade is developing JADE101 with the goal of transforming the treatment paradigm for IgAN and other autoimmune diseases. The company believes selective anti-APRIL therapies are poised to become foundational treatments in IgAN, potentially moving to frontline therapy by delivering disease-modifying efficacy, including durable reductions in pathogenic IgA and proteinuria and stabilization of kidney function, without unnecessary immune suppression.

Key upcoming anticipated JADE101 milestones:

• Phase 1 interim results from the ongoing healthy volunteer study expected in the first half of 2026 are anticipated to define dose and dose interval selection for Phase 2 and Phase 3 IgAN patient studies.
• Jade expects to initiate a Phase 2 clinical trial in patients with IgAN mid-2026, with preliminary data anticipated in 2027.

JADE201: Half-Life Extended, Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

JADE201 is a half-life extended, enhanced effector function monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R). JADE201 is designed to build on the differentiated dual mechanism of prior anti-BAFF-R antibodies to deplete B cells, while addressing limitations such as short half-life through the incorporation of half-life extension technology, with the goal of prolonging receptor coverage and enabling less frequent subcutaneous dosing. This approach has the potential to deliver deeper and more durable B-cell depletion than existing therapies, translating into enhanced efficacy and reduced treatment burden for patients.

Key upcoming anticipated JADE201 milestones:

• A first-in-human study initially evaluating JADE201 in patients with rheumatoid arthritis is expected to begin in the second quarter of 2026, with interim data anticipated in 2027.
  • The randomized, placebo-controlled, single ascending dose trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics, incorporating biomarker-rich endpoints such as BAFF-R occupancy, soluble BAFF levels, and B-cell subpopulation profiling.
  • With its differentiated mechanism and engineering, JADE201 has broad potential across a range of autoimmune diseases validated by BAFF-R biology.
    
    

Broader Autoimmune Pipeline

Key pipeline milestones:

• Nominated development candidate, JADE301, an undisclosed antibody program.
  • JADE301 is currently in preclinical testing and is expected to enter first-in-human study in the first half of 2027.
  • Further details on JADE301 are expected to be disclosed in the second half of 2026.
    
    

Financial Update

Jade expects to report that its cash, cash equivalents and investments as of December 31, 2025 were approximately $336 million, which is expected to fund operations into the first half of 2028.

Jade has not yet completed its quarter- or year-end financial close process for the period ended December 31, 2025. This estimate of the Company’s cash, cash equivalents and investments as of December 31, 2025 is preliminary, has not been audited and is subject to change upon completion of the company’s financial statement closing procedures and the completion of the audit of the 2025 financial statements. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it.

J.P. Morgan Healthcare Conference Presentation

Jade to present a company overview and 2026 outlook at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 a.m. PT. A live audio webcast of the presentation and a replay will be available on the Company’s website at JadeBiosciences.com. Members of the Jade management team will host one-on-one investor meetings during the conference.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade’s ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and JADE301; the expected timelines for interim data from the Phase 1 clinical trial of JADE101, initiation of the Phase 2 clinical trial of JADE101 and the Phase 1 clinical trials of JADE201 and JADE301, and the availability of data from such trials; plans for future clinical trials; the potential for anti-APRIL therapies to become foundational treatments or frontline therapy for IgAN; the potential of Jade’s product candidates to become best-in-class therapies; their potential therapeutic uses, efficacy, durability, safety profiles, and dosing; and the expectation that Jade’s runway will extend into the first half of 2028. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the Phase 1 clinical trial of JADE101, the planned trials of JADE101, JADE201 and JADE301, and any other clinical trials may be delayed or may not demonstrate desirable efficacy; adverse events and safety signals may occur; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade’s product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; enrollment or regulatory challenges; risks associated with Jade’s dependence on third-party vendors for the development, manufacture and supply of its product candidates; Jade may use its capital resources sooner than expected; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.

Jade Biosciences Contact

Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134

FAQ

When will Jade Biosciences (JBIO) present at the 44th Annual J.P. Morgan Healthcare Conference?

Jade will present on January 15, 2026 at 11:15 a.m. PT with a live audio webcast and replay available on its website.

What clinical milestone is expected for JADE101 (JBIO) in the first half of 2026?

Interim biomarker-rich Phase 1 results for JADE101 are expected in the first half of 2026 to inform dosing for Phase 2.

When does JBIO plan to start the Phase 2 trial of JADE101 in IgA nephropathy?

Jade expects to initiate a Phase 2 clinical trial in patients with IgA nephropathy mid-2026, with preliminary data anticipated in 2027.

What is the timeline for JADE201 first-in-human studies (JBIO)?

A first-in-human study of JADE201 in rheumatoid arthritis patients is expected to begin in Q2 2026, with interim data anticipated in 2027.

How long is JBIO's cash runway based on the Dec 31, 2025 estimate?

Jade reported approximately $336 million of cash and investments as of Dec 31, 2025, expected to fund operations into the first half of 2028.

When will JBIO disclose more details about the nominated program JADE301?

JADE301 is expected to enter first-in-human study in H1 2027, and further details are expected to be disclosed in the second half of 2026.